250 related articles for article (PubMed ID: 33933681)
21. Cytotoxic T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule.
Chen BP; Madrigal A; Parham P
J Exp Med; 1990 Sep; 172(3):779-88. PubMed ID: 2117634
[TBL] [Abstract][Full Text] [Related]
22. The role of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing and presentation.
Alfonso C; Liljedahl M; Winqvist O; Surh CD; Peterson PA; Fung-Leung WP; Karlsson L
Immunol Rev; 1999 Dec; 172():255-66. PubMed ID: 10631951
[TBL] [Abstract][Full Text] [Related]
23. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading.
van Ham SM; Tjin EP; Lillemeier BF; Grüneberg U; van Meijgaarden KE; Pastoors L; Verwoerd D; Tulp A; Canas B; Rahman D; Ottenhoff TH; Pappin DJ; Trowsdale J; Neefjes J
Curr Biol; 1997 Dec; 7(12):950-7. PubMed ID: 9382849
[TBL] [Abstract][Full Text] [Related]
24. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP
Anczurowski M; Yamashita Y; Nakatsugawa M; Ochi T; Kagoya Y; Guo T; Wang CH; Rahman MA; Saso K; Butler MO; Hirano N
Sci Rep; 2018 Mar; 8(1):4804. PubMed ID: 29555965
[TBL] [Abstract][Full Text] [Related]
26. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
27. Altered antigen presentation in mice lacking H2-O.
Liljedahl M; Winqvist O; Surh CD; Wong P; Ngo K; Teyton L; Peterson PA; Brunmark A; Rudensky AY; Fung-Leung WP; Karlsson L
Immunity; 1998 Feb; 8(2):233-43. PubMed ID: 9492004
[TBL] [Abstract][Full Text] [Related]
28. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
[TBL] [Abstract][Full Text] [Related]
29. The human leukocyte antigen-presented ligandome of B lymphocytes.
Hassan C; Kester MG; de Ru AH; Hombrink P; Drijfhout JW; Nijveen H; Leunissen JA; Heemskerk MH; Falkenburg JH; van Veelen PA
Mol Cell Proteomics; 2013 Jul; 12(7):1829-43. PubMed ID: 23481700
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of peptide repertoire selection by HLA-DM.
Pos W; Sethi DK; Wucherpfennig KW
Trends Immunol; 2013 Oct; 34(10):495-501. PubMed ID: 23835076
[TBL] [Abstract][Full Text] [Related]
31. Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines.
Lin X; Wang X; Capek HL; Simone LC; Tuli A; Morris CR; Reber AJ; Solheim JC
Cancer Immunol Immunother; 2009 May; 58(5):729-36. PubMed ID: 18828016
[TBL] [Abstract][Full Text] [Related]
32. Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity.
Mommen GP; Marino F; Meiring HD; Poelen MC; van Gaans-van den Brink JA; Mohammed S; Heck AJ; van Els CA
Mol Cell Proteomics; 2016 Apr; 15(4):1412-23. PubMed ID: 26764012
[TBL] [Abstract][Full Text] [Related]
33. Reanalysis of Immunopeptidomics Datasets Provides Mechanistic Insight into TAPBPR-Mediated Peptide Editing on HLA-A, -B and -C Molecules.
Altenburg AF; Morley JL; Bauer J; Walz JS; Boyle LH
Wellcome Open Res; 2024; 9():113. PubMed ID: 38800518
[TBL] [Abstract][Full Text] [Related]
34. Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.
Partridge T; Nicastri A; Kliszczak AE; Yindom LM; Kessler BM; Ternette N; Borrow P
Front Immunol; 2018; 9():912. PubMed ID: 29780384
[TBL] [Abstract][Full Text] [Related]
35. Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA.
Dörfel D; Appel S; Grünebach F; Weck MM; Müller MR; Heine A; Brossart P
Blood; 2005 Apr; 105(8):3199-205. PubMed ID: 15618468
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis.
Zhao D; Hajiaghamohseni LM; Liu X; Szulc ZM; Bai A; Bielawska A; Norris JS; Reddy SV; Hannun YA; Haque A
Cytokine; 2020 Nov; 135():155219. PubMed ID: 32738771
[TBL] [Abstract][Full Text] [Related]
37. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
38. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
39. Peptide linkage to the α-subunit of MHCII creates a stably inverted antigen presentation complex.
Schlundt A; Günther S; Sticht J; Wieczorek M; Roske Y; Heinemann U; Freund C
J Mol Biol; 2012 Oct; 423(3):294-302. PubMed ID: 22820093
[TBL] [Abstract][Full Text] [Related]
40. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments.
Sanderson F; Kleijmeer MJ; Kelly A; Verwoerd D; Tulp A; Neefjes JJ; Geuze HJ; Trowsdale J
Science; 1994 Dec; 266(5190):1566-9. PubMed ID: 7985027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
